codon-optimized sequence for mers s (emc strain) Search Results


mers s protein  (Sino Biological)
93
Sino Biological mers s protein
Mers S Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mers s protein/product/Sino Biological
Average 93 stars, based on 1 article reviews
mers s protein - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
mers-s gene  (GenScript corporation)
90
GenScript corporation mers-s gene
Construction of adenoviral vector vaccines. (A) A shuttle vector carrying the <t>codon-optimized</t> <t>MERS-S</t> gene encoding full-length protein (1-1353) or MERS-S1 gene encoding the soluble form (1-725) was designated, as shown in the diagram. The positions of the RBD (small dots) and transmembrane domain (stripes) are indicated and S is divided into two subdomains, S1 and S2, at position 751 . The vector was used to generate recombinant replication-deficient adenoviruses by homologous recombination with the adenoviral genomic DNA. (B) Detection of the MERS-S protein by immunocytochemical staining of A549 cells infected with Ad5.MERS-S or Ad5.MERS-S1 (5 MOI) using sera from mice obtained at three weeks after the second Ad5.MERS-S1 boost. As a negative control, mock or AdΨ5-infected cells were treated the same.
Mers S Gene, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mers-s gene/product/GenScript corporation
Average 90 stars, based on 1 article reviews
mers-s gene - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
codon-optimized mers s-containing sequences for a c-terminal c9 epitope tag  (GenScript corporation)
90
GenScript corporation codon-optimized mers s-containing sequences for a c-terminal c9 epitope tag
Construction of adenoviral vector vaccines. (A) A shuttle vector carrying the <t>codon-optimized</t> <t>MERS-S</t> gene encoding full-length protein (1-1353) or MERS-S1 gene encoding the soluble form (1-725) was designated, as shown in the diagram. The positions of the RBD (small dots) and transmembrane domain (stripes) are indicated and S is divided into two subdomains, S1 and S2, at position 751 . The vector was used to generate recombinant replication-deficient adenoviruses by homologous recombination with the adenoviral genomic DNA. (B) Detection of the MERS-S protein by immunocytochemical staining of A549 cells infected with Ad5.MERS-S or Ad5.MERS-S1 (5 MOI) using sera from mice obtained at three weeks after the second Ad5.MERS-S1 boost. As a negative control, mock or AdΨ5-infected cells were treated the same.
Codon Optimized Mers S Containing Sequences For A C Terminal C9 Epitope Tag, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/codon-optimized mers s-containing sequences for a c-terminal c9 epitope tag/product/GenScript corporation
Average 90 stars, based on 1 article reviews
codon-optimized mers s-containing sequences for a c-terminal c9 epitope tag - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Construction of adenoviral vector vaccines. (A) A shuttle vector carrying the codon-optimized MERS-S gene encoding full-length protein (1-1353) or MERS-S1 gene encoding the soluble form (1-725) was designated, as shown in the diagram. The positions of the RBD (small dots) and transmembrane domain (stripes) are indicated and S is divided into two subdomains, S1 and S2, at position 751 . The vector was used to generate recombinant replication-deficient adenoviruses by homologous recombination with the adenoviral genomic DNA. (B) Detection of the MERS-S protein by immunocytochemical staining of A549 cells infected with Ad5.MERS-S or Ad5.MERS-S1 (5 MOI) using sera from mice obtained at three weeks after the second Ad5.MERS-S1 boost. As a negative control, mock or AdΨ5-infected cells were treated the same.

Journal: Vaccine

Article Title: Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

doi: 10.1016/j.vaccine.2014.08.058

Figure Lengend Snippet: Construction of adenoviral vector vaccines. (A) A shuttle vector carrying the codon-optimized MERS-S gene encoding full-length protein (1-1353) or MERS-S1 gene encoding the soluble form (1-725) was designated, as shown in the diagram. The positions of the RBD (small dots) and transmembrane domain (stripes) are indicated and S is divided into two subdomains, S1 and S2, at position 751 . The vector was used to generate recombinant replication-deficient adenoviruses by homologous recombination with the adenoviral genomic DNA. (B) Detection of the MERS-S protein by immunocytochemical staining of A549 cells infected with Ad5.MERS-S or Ad5.MERS-S1 (5 MOI) using sera from mice obtained at three weeks after the second Ad5.MERS-S1 boost. As a negative control, mock or AdΨ5-infected cells were treated the same.

Article Snippet: The MERS-S (GenBank JX869059 ) gene was codon-optimized for optimal expression in mammalian cells using the UpGene codon optimization algorithm and synthesized (GenScript). pAd/MERS-S was generated by subcloning the codon-optimized MERS-S gene into the shuttle vector, pAdlox (GenBank U62024 ), at SalI/NotI sites.

Techniques: Plasmid Preparation, Recombinant, Homologous Recombination, Staining, Infection, Negative Control

Antibodies in sera of mice immunized with Ad5.MERS-S or Ad5.MERS-S1 bind to MERS-S-expressing cells. HEK 293 cells were transfected with control pAd (black line) or with pAd/MERS-S (gray shaded area). At 36 h post-transfection, MERS-S expressions at the cell surface were analyzed with pooled murine sera obtained after the first intramuscular immunization with Ad5.MERS-S, Ad5.MERS-S1, AdΨ5, or pre-immunized naïve mouse sera as a control followed by staining with PE-conjugated anti-mouse IgG and flow cytometric analysis. Numbers represent the percentage of cells positive for spike proteins.

Journal: Vaccine

Article Title: Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

doi: 10.1016/j.vaccine.2014.08.058

Figure Lengend Snippet: Antibodies in sera of mice immunized with Ad5.MERS-S or Ad5.MERS-S1 bind to MERS-S-expressing cells. HEK 293 cells were transfected with control pAd (black line) or with pAd/MERS-S (gray shaded area). At 36 h post-transfection, MERS-S expressions at the cell surface were analyzed with pooled murine sera obtained after the first intramuscular immunization with Ad5.MERS-S, Ad5.MERS-S1, AdΨ5, or pre-immunized naïve mouse sera as a control followed by staining with PE-conjugated anti-mouse IgG and flow cytometric analysis. Numbers represent the percentage of cells positive for spike proteins.

Article Snippet: The MERS-S (GenBank JX869059 ) gene was codon-optimized for optimal expression in mammalian cells using the UpGene codon optimization algorithm and synthesized (GenScript). pAd/MERS-S was generated by subcloning the codon-optimized MERS-S gene into the shuttle vector, pAdlox (GenBank U62024 ), at SalI/NotI sites.

Techniques: Expressing, Transfection, Staining

Characterization of MERS-S1-specific immune responses induced by adenoviral vector vaccines. BALB/c mice were immunized intramuscularly with 1 × 10 11 viral particles of AdΨ5 (C), Ad5.MERS-S (S), or Ad5.MERS-S1 (S1), respectively, and boosted intranasally with the same amount of each virus three weeks later. MERS-S1-specific IgG1 (A) and IgG2a (B) antibody levels were measured at the indicated time points by ELISA. Statically significant differences (Tukey's test) are marked by bars and asterisks. * P < 0.05; ** P < 0.005; *** P < 0.001; **** P < 0.0001.

Journal: Vaccine

Article Title: Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

doi: 10.1016/j.vaccine.2014.08.058

Figure Lengend Snippet: Characterization of MERS-S1-specific immune responses induced by adenoviral vector vaccines. BALB/c mice were immunized intramuscularly with 1 × 10 11 viral particles of AdΨ5 (C), Ad5.MERS-S (S), or Ad5.MERS-S1 (S1), respectively, and boosted intranasally with the same amount of each virus three weeks later. MERS-S1-specific IgG1 (A) and IgG2a (B) antibody levels were measured at the indicated time points by ELISA. Statically significant differences (Tukey's test) are marked by bars and asterisks. * P < 0.05; ** P < 0.005; *** P < 0.001; **** P < 0.0001.

Article Snippet: The MERS-S (GenBank JX869059 ) gene was codon-optimized for optimal expression in mammalian cells using the UpGene codon optimization algorithm and synthesized (GenScript). pAd/MERS-S was generated by subcloning the codon-optimized MERS-S gene into the shuttle vector, pAdlox (GenBank U62024 ), at SalI/NotI sites.

Techniques: Plasmid Preparation, Enzyme-linked Immunosorbent Assay

Induction of neutralizing antibodies in mice vaccinated with AdΨ5 (A), Ad5.MERS-S (B), or Ad5.MERS-S1 (C), respectively, as described in . MERS-CoV-neutralizing titers (VNTs) were measured every week after primary immunization using Vero cells by determining the highest dilution inhibiting MERS-CoV infection by 100%.

Journal: Vaccine

Article Title: Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

doi: 10.1016/j.vaccine.2014.08.058

Figure Lengend Snippet: Induction of neutralizing antibodies in mice vaccinated with AdΨ5 (A), Ad5.MERS-S (B), or Ad5.MERS-S1 (C), respectively, as described in . MERS-CoV-neutralizing titers (VNTs) were measured every week after primary immunization using Vero cells by determining the highest dilution inhibiting MERS-CoV infection by 100%.

Article Snippet: The MERS-S (GenBank JX869059 ) gene was codon-optimized for optimal expression in mammalian cells using the UpGene codon optimization algorithm and synthesized (GenScript). pAd/MERS-S was generated by subcloning the codon-optimized MERS-S gene into the shuttle vector, pAdlox (GenBank U62024 ), at SalI/NotI sites.

Techniques: Infection